Consumer staples de-rating / GLP-1 demand (new) Terminal-decline de-rating ◆

WSJ Heard on the Street (Carol Ryan, Jul 5 2026): US spirits volume has fallen four straight years on moderation, wellness, GLP-1 weight-loss drugs, cannabis/THC substitution and Gen Z abstinence, and the market has re-rated spirits leaders Diageo (DEO) and Pernod Ricard (PRNDY) to tobacco-like multiples (Pernod now below British American Tobacco and Altria on expected earnings; Diageo's multiple at 2009 levels). The contrarian tell it flags: booming ready-to-drink canned cocktails (+20–30%/yr) and smaller pack sizes suggest part of the volume loss is squeezed budgets, not secular abstinence — so the deepest de-rated leaders (Diageo) may be value, not value traps, if drinking isn't dying the way smoking did. App Economy (Jul 11): the wellness pivot is now the staples' own strategy — PepsiCo's "permissible portfolio" (protein-fortified snacks, portion-controlled multipacks) hit $3B growing double digits, and General Mills pivoted from price reinvestment to functional-nutrition premiumization (protein/fiber across Cheerios and legacy brands) — the incumbents converting the GLP-1/wellness demand shift into premium mix rather than fighting it. 2026-AUG-08 — App Economy (PRO): the GLP-1 franchise has flipped from price to access — Lilly grew revenue 48% on a 60% volume increase against a 13% decline in realized price (international Mounjaro more than doubled on deliberate cuts including China reimbursement; oral Foundayo's first quarter $98M; retatrutide through three more positive Phase 3s). Novo's oral Wegovy +40% Q/Q past 5M prescriptions while injectable Wegovy grew 1% cc with US sales still guided down. Cheaper, orally-dosed GLP-1s reaching far more people is the mechanism behind the staples' terminal-decline framing. 2026-08-17 — first constructive datapoint on the group in the hub, deliberately small: after "a just devastatingly bad couple years," "Kraft Heinz, Hershey's all starting to bottom here. I think they're worth a look" — immediately qualified with "I would hardly call the sector leader in the market," and staples stay "probably still near the bottom" of the defensive ranking, behind health care. A bombed-out group showing signs of life, not a rotation. (Verrone on Eisman Ep 73, Aug 17) 2026-AUG-15 — App Economy Insights PRO (Hims & Hers Q2): the distributor side of the access-over-price flip. Revenue +38% to $753M on branded GLP-1 volume, but gross margin fell from 76% a year ago to 64% and "management expects that lower margin profile to persist," with free cash flow swinging to −$68M even as FY26 revenue guidance rose to $3.1–$3.3B. Cheap access is being bought with structural margin: Hims is "increasingly looking like a lower-gross-margin global healthcare platform rather than the exceptionally high-margin telehealth model investors were used to." Slegers 2026-JUL-23: the demand side of the GLP-1 shock, sized. “Over 1 billion people are overweight,” and analysts project the obesity drug market to “grow by 27.0% per year, reaching $90 billion by 2035” (above $50bn by 2030), with Eli Lilly and Novo Nordisk holding it as a duopoly and revenue that is “extremely sticky” because “patients stay on these drugs long-term.” He passes on LLY on price — a 32.2x forward PE against a 30.3x 10-year average and a reverse DCF requiring 18.9% annual net-income growth against his own 10-15% estimate — and prefers NVO, whose oral Wegovy and higher-dose injection were approved EU-wide on 2026-JUL-16 (2026-AUG-02). Slegers 2026-AUG-23: the GLP-1 winner is now itself being marked down on competition — Novo Nordisk cut BUY → HOLD "due to increasing competition" while trading 54.5% below the firm's own fair value at 12.3x forward against a 27.8x five-year average. The 2026-SEP-01 letter makes it concrete: analyst EPS is expected to be flat from 23.03 (2025) to 22.98 (2028), a 7% 3-5yr CAGR (the lowest of 21 holdings) and a modelled three-year return of 3.43%, almost all of it the dividend. The position is marked for reduction. Slegers 2026-MAY-07: the GLP-1 leadership question flips inside three weeks. On 2026-APR-19 he quotes Terry Smith on Novo Nordisk having "moved from a triumph to a tragedy… they managed to snatch defeat from the jaws of victory in the core US market" against Eli Lilly, and holds it at Medium conviction. By 7 May the disclosed evidence has turned: guidance raised with profit, revenue and operating profit all ahead, "the Wegovy pill was the most successful drug launch ever", over 2 million total prescriptions, 65% of all new US prescriptions, and an OpenAI drug-discovery partnership — rated STRONG BUY at a 19.2% expected return and 56.3% undervaluation on a 12.3x forward PE, its lowest ever. Slegers 2026-MAY-24: the GLP-1 price-versus-volume trade laid out on Novo Nordisk, which "now trades at the same price than before (!) it launched Ozempic". The three fears: a US government agreement cutting Wegovy and Ozempic from over $1,000 to as low as $149 for some doses, lost semaglutide data exclusivity in Canada and India, and margin pressure from manufacturing scale-up. Against them the launch data for the Wegovy pill: 170,000 patients in four weeks, over 1 million treated by end-Q1, with Eli Lilly's oral Foundayo "selling at much lower volumes" and new data showing more weight loss and fewer side effects for Novo's pill. The thesis is that a cheap oral reaches "millions of people who would never agree to give themselves a shot" — volume, not price, is where the value sits. Pieter Slegers (Compounding Quality), 2026-APR-09: extends the consumer-brand de-rating question from staples to beauty, and puts the moat itself in doubt. On L'Oréal (OR.PA) — the world's number one at a 14.5% share, 74.3% gross margin, 7.8/10 Quality Score — the write-up asks the question the category usually avoids: "Year after year, L'Oréal spends roughly 32% of its revenue on advertising and promotion expenses. It makes you wonder what is doing the heavy lifting: the brand or the advertising?" The named erosion mechanism is distribution rather than demand: "Digitalization allows smaller competitors to reach customers online. They don't have to battle for expensive shelf space anymore" — which removes the half of the scale advantage that shelf space used to buy, while the advertising bill stays. The de-rating is already visible (forward PE 27.0x against a 31.5x ten-year average, "the valuation of L'Oréal came down significantly since 2022") and the verdict is still a pass, on growth rather than price: expected revenue growth of 5.0% against a reverse DCF demanding 13.0% FCF growth versus 8.7% delivered over a decade. Entry named at 20x earnings, i.e. €271 against €367.4. 2026-SEP-08 (CNBC Halftime): the thesis crosses from staples into quick-serve restaurants, and the desk cannot answer it. Terranova: "all these quick serve restaurant names… have not been trading well. I don't hear anyone present the reasoning that potentially these GLP-1s are contributing to quick serve not seeing the type of demand it saw 5, 6, 7 years ago… McDonald's, Shack, Wendy's, it's universal across the board… you can even throw up Domino's." Belski answers per-company and extends it as a reductio (Mondelez, Coca-Cola, General Mills — "people are not eating those names") that fails because Lebenthal simply agrees ("consumer staples has been nauseous"), and concedes "I've never thought about the GLP-1 side of things." Wapner names the untested control: the Lilly chart runs the opposite way. 2026-SEP-04 (Peter Lukacs, 6-stock tobacco comparison): tobacco is a structural but gradual volume decline, cushioned by population growth, and demand barely falls when prices rise (~0.4 in high-income countries: +10% price = −4% volume), so price increases still outrun it. Reduced-risk products are the offset (PM ~42% smoke-free via IQOS/Zyn). Valuation rather than quality decides: Imperial Brands ~12% FCF yield / ~100% DCF upside and BAT ~10% / ~60% are the buys; Philip Morris is the best company but ~4% FCF yield and negative DCF upside; Japan Tobacco is expensive and least profitable. Chris D'Agnes (Hamlin Capital, 2026-AUG-10): staples/CPG is 'a very tough area' that dividend investors should avoid - dividend cutting has started (Conagra just cut); 'are General Mills and Campbell next?' High yields on these aristocrats are warnings, not bargains. 2026-SEP-19 (Jeff Weniger): Campbell's is "going to be a big problem". It faces aluminum can costs in a commodities bull market plus GLP-1s cutting calorie demand (still low penetration, a mega-trend), and it has just cut its dividend. PepsiCo has partial offsets in pricing power and brand pull against private-label trade-down. Knock-on: GLP-1s also dent demand for Medtronic and Stryker devices (fewer knee replacements). "I'd be long consumer discretionary, frankly."